Abstract

DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLY

Paras B. Pophalkar*, R. B. Wakade, Sachin U. Hole, Chetan Y. Kadam, Rajnandni S. Suroshe and Wrushali A. Panchale

Abstract

Aim of this study is to develop medicated jelly of Ondansetron for effective delivery in paediatric patient. It is the prototype of a new class of antiemetic drugs developed to control cancer chemotherapy/radiotherapy induced vomiting, and later found to be highly effective in postoperative nausea and vomiting as well. It blocks the depolarizing action of 5-HT through 5-HT3 receptors on vagal afferents in the G.I.T. as well as in NTS and CTZ. It is convenient to administer as compared with liquid dosage form in pediatric. This formulation is very good alternative for drug delivery to paediatrics, geriatric and dysphagic patients. Oral jellies have significant advantages of both solid and liquid dosage forms, as they remain solid during storage which aid in stability of dosage forms and transform in liquid like form within few seconds to minute after its administration. Medicated jelly is prepared by gelling agent like Gelatin and carbopol 934, other excipients and using sugar syrup. In-vitro dissolution were applied to interpret the release of Ondansetron. The F3 formulation was best and optimized formulation on the basis of dissolution profile and because of gelatin as jelling agent it was non sticky as compaired with carbopol 934 so that weight variation not occurred and having better dissolution.

Keywords: Ondansetron, Gelatin, Carbopol 934.